Research Progress in Oncolytic Virus Combined with Small Molecule Inhibitors for Cancer Treatment
- 公共卫生－已发表论文 
溶瘤病毒因具有选择性杀伤肿瘤细胞的特性,已成为目前较有前景的肿瘤治疗类药物。溶瘤病毒疗法的安全性和有效性在临床中已得到证实,但由于恶性肿瘤高度的; 异质性和复杂性使得溶瘤病毒单药治疗肿瘤的效果受限,因此溶瘤病毒联合其他肿瘤治疗药物一起协同治疗肿瘤将是未来肿瘤治疗的重要发展方向之一,有望为肿瘤; 的治疗带来新的突破。新近研究表明,不同的小分子抑制剂可通过多种机制控制肿瘤生长,其在体外协同溶瘤病毒能达到更优的肿瘤治疗效果。本文就目前溶瘤病毒; 联合小分子抑制剂治疗肿瘤的研究进展进行综述。Due to thier characteristic feature of selectively killing cancer cells,; oncolytic virus has been considered one of the promising agents for; cancer treatment. The safety and efficacy of oncolytic virotherapy has; been proved in multiple clinical trials. But so far oncolytic virus has; been demonstrated limited efficacy as single therapeutic agent in the; clinical setting of malignant cancer with high heterogeneity and; complexity. Combination treatment of oncolytic virus and other; anti-cancer drugs could be an important research direction in the; future, which is expected to bring new therapeutic options for cancer; patients. Recent research has demonstrated that small molecule; inhibitors can target cancer cells by different mechanisms. Combination; of small molecule inhibitors with oncolytic virus may result in; synergistic antitumor effects both in vivo and in vitro. We summarize; current progress of combination therapy using oncolytic virus and small; molecule inhibitors for cancer treatment.